Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

未提供0 个研究点目标入组 170 人开始时间: 待定

适应症

试验速览

暂无简介。

•Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit.
•Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.

•Participant is not eligible for study treatment per the parent study eligibility criteria.
•Participants who have completed treatment with the study drugs, progressed on prior study treatment, or discontinued study treatment due to toxicity in the parent study are not eligible to receive study drug in this study.
•Participants not receiving clinical benefit from parent study drug as assessed by the investigator.
•Other protocol defined inclusion/exclusion criteria applies.

发起方

未提供